Copyright Reports & Markets. All rights reserved.

Global Hemophilia Drugs Market Research Report 2021

Request for Sample of this report
Buy now

1 Hemophilia Drugs Market Overview

  • 1.1 Product Overview and Scope of Hemophilia Drugs
  • 1.2 Hemophilia Drugs Segment by Type
    • 1.2.1 Global Hemophilia Drugs Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Hemophilia A
    • 1.2.3 Inhibitors
    • 1.2.4 Hemophilia B
    • 1.2.5 Von Willebrand Disease
  • 1.3 Hemophilia Drugs Segment by Application
    • 1.3.1 Hemophilia Drugs Sales Comparison by Application: (2021-2027)
    • 1.3.2 Recombinant Therapies
    • 1.3.3 Plasma-Derived Therapies
  • 1.4 Global Hemophilia Drugs Market Size Estimates and Forecasts
    • 1.4.1 Global Hemophilia Drugs Revenue 2016-2027
    • 1.4.2 Global Hemophilia Drugs Sales 2016-2027
    • 1.4.3 Hemophilia Drugs Market Size by Region: 2016 Versus 2021 Versus 2027

2 Hemophilia Drugs Market Competition by Manufacturers

  • 2.1 Global Hemophilia Drugs Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Hemophilia Drugs Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Hemophilia Drugs Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Hemophilia Drugs Manufacturing Sites, Area Served, Product Type
  • 2.5 Hemophilia Drugs Market Competitive Situation and Trends
    • 2.5.1 Hemophilia Drugs Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Hemophilia Drugs Players Market Share by Revenue
    • 2.5.3 Global Hemophilia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Hemophilia Drugs Retrospective Market Scenario by Region

  • 3.1 Global Hemophilia Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global Hemophilia Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America Hemophilia Drugs Market Facts & Figures by Country
    • 3.3.1 North America Hemophilia Drugs Sales by Country
    • 3.3.2 North America Hemophilia Drugs Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Hemophilia Drugs Market Facts & Figures by Country
    • 3.4.1 Europe Hemophilia Drugs Sales by Country
    • 3.4.2 Europe Hemophilia Drugs Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Hemophilia Drugs Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Hemophilia Drugs Sales by Region
    • 3.5.2 Asia Pacific Hemophilia Drugs Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Hemophilia Drugs Market Facts & Figures by Country
    • 3.6.1 Latin America Hemophilia Drugs Sales by Country
    • 3.6.2 Latin America Hemophilia Drugs Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Hemophilia Drugs Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Hemophilia Drugs Sales by Country
    • 3.7.2 Middle East and Africa Hemophilia Drugs Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 U.A.E

4 Global Hemophilia Drugs Historic Market Analysis by Type

  • 4.1 Global Hemophilia Drugs Sales Market Share by Type (2016-2021)
  • 4.2 Global Hemophilia Drugs Revenue Market Share by Type (2016-2021)
  • 4.3 Global Hemophilia Drugs Price by Type (2016-2021)

5 Global Hemophilia Drugs Historic Market Analysis by Application

  • 5.1 Global Hemophilia Drugs Sales Market Share by Application (2016-2021)
  • 5.2 Global Hemophilia Drugs Revenue Market Share by Application (2016-2021)
  • 5.3 Global Hemophilia Drugs Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Baxalta
    • 6.1.1 Baxalta Corporation Information
    • 6.1.2 Baxalta Description and Business Overview
    • 6.1.3 Baxalta Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Baxalta Product Portfolio
    • 6.1.5 Baxalta Recent Developments/Updates
  • 6.2 Bayer
    • 6.2.1 Bayer Corporation Information
    • 6.2.2 Bayer Description and Business Overview
    • 6.2.3 Bayer Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Bayer Product Portfolio
    • 6.2.5 Bayer Recent Developments/Updates
  • 6.3 CSL Behring
    • 6.3.1 CSL Behring Corporation Information
    • 6.3.2 CSL Behring Description and Business Overview
    • 6.3.3 CSL Behring Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 CSL Behring Product Portfolio
    • 6.3.5 CSL Behring Recent Developments/Updates
  • 6.4 Pfizer
    • 6.4.1 Pfizer Corporation Information
    • 6.4.2 Pfizer Description and Business Overview
    • 6.4.3 Pfizer Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Pfizer Product Portfolio
    • 6.4.5 Pfizer Recent Developments/Updates
  • 6.5 Alnylam Pharmaceuticals
    • 6.5.1 Alnylam Pharmaceuticals Corporation Information
    • 6.5.2 Alnylam Pharmaceuticals Description and Business Overview
    • 6.5.3 Alnylam Pharmaceuticals Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Alnylam Pharmaceuticals Product Portfolio
    • 6.5.5 Alnylam Pharmaceuticals Recent Developments/Updates
  • 6.6 BioMarin
    • 6.6.1 BioMarin Corporation Information
    • 6.6.2 BioMarin Description and Business Overview
    • 6.6.3 BioMarin Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 BioMarin Product Portfolio
    • 6.6.5 BioMarin Recent Developments/Updates
  • 6.7 Catalyst Biosciences
    • 6.6.1 Catalyst Biosciences Corporation Information
    • 6.6.2 Catalyst Biosciences Description and Business Overview
    • 6.6.3 Catalyst Biosciences Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Catalyst Biosciences Product Portfolio
    • 6.7.5 Catalyst Biosciences Recent Developments/Updates
  • 6.8 Dimension Therapeutics
    • 6.8.1 Dimension Therapeutics Corporation Information
    • 6.8.2 Dimension Therapeutics Description and Business Overview
    • 6.8.3 Dimension Therapeutics Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Dimension Therapeutics Product Portfolio
    • 6.8.5 Dimension Therapeutics Recent Developments/Updates
  • 6.9 F. Hoffmann-La Roche
    • 6.9.1 F. Hoffmann-La Roche Corporation Information
    • 6.9.2 F. Hoffmann-La Roche Description and Business Overview
    • 6.9.3 F. Hoffmann-La Roche Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 F. Hoffmann-La Roche Product Portfolio
    • 6.9.5 F. Hoffmann-La Roche Recent Developments/Updates
  • 6.10 Grifols
    • 6.10.1 Grifols Corporation Information
    • 6.10.2 Grifols Description and Business Overview
    • 6.10.3 Grifols Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Grifols Product Portfolio
    • 6.10.5 Grifols Recent Developments/Updates
  • 6.11 Octapharma
    • 6.11.1 Octapharma Corporation Information
    • 6.11.2 Octapharma Hemophilia Drugs Description and Business Overview
    • 6.11.3 Octapharma Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Octapharma Product Portfolio
    • 6.11.5 Octapharma Recent Developments/Updates
  • 6.12 Sangamo Biosciences
    • 6.12.1 Sangamo Biosciences Corporation Information
    • 6.12.2 Sangamo Biosciences Hemophilia Drugs Description and Business Overview
    • 6.12.3 Sangamo Biosciences Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 Sangamo Biosciences Product Portfolio
    • 6.12.5 Sangamo Biosciences Recent Developments/Updates
  • 6.13 Spark Therapeutics
    • 6.13.1 Spark Therapeutics Corporation Information
    • 6.13.2 Spark Therapeutics Hemophilia Drugs Description and Business Overview
    • 6.13.3 Spark Therapeutics Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.13.4 Spark Therapeutics Product Portfolio
    • 6.13.5 Spark Therapeutics Recent Developments/Updates
  • 6.14 Swedish Orphan Biovitrum
    • 6.14.1 Swedish Orphan Biovitrum Corporation Information
    • 6.14.2 Swedish Orphan Biovitrum Hemophilia Drugs Description and Business Overview
    • 6.14.3 Swedish Orphan Biovitrum Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.14.4 Swedish Orphan Biovitrum Product Portfolio
    • 6.14.5 Swedish Orphan Biovitrum Recent Developments/Updates

7 Hemophilia Drugs Manufacturing Cost Analysis

  • 7.1 Hemophilia Drugs Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Hemophilia Drugs
  • 7.4 Hemophilia Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Hemophilia Drugs Distributors List
  • 8.3 Hemophilia Drugs Customers

9 Hemophilia Drugs Market Dynamics

  • 9.1 Hemophilia Drugs Industry Trends
  • 9.2 Hemophilia Drugs Growth Drivers
  • 9.3 Hemophilia Drugs Market Challenges
  • 9.4 Hemophilia Drugs Market Restraints

10 Global Market Forecast

  • 10.1 Hemophilia Drugs Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Hemophilia Drugs by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Hemophilia Drugs by Type (2022-2027)
  • 10.2 Hemophilia Drugs Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Hemophilia Drugs by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Hemophilia Drugs by Application (2022-2027)
  • 10.3 Hemophilia Drugs Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Hemophilia Drugs by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Hemophilia Drugs by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Hemophilia A
    Inhibitors
    Hemophilia B
    Von Willebrand Disease

    Segment by Application
    Recombinant Therapies
    Plasma-Derived Therapies

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E

    By Company
    Baxalta
    Bayer
    CSL Behring
    Pfizer
    Alnylam Pharmaceuticals
    BioMarin
    Catalyst Biosciences
    Dimension Therapeutics
    F. Hoffmann-La Roche
    Grifols
    Octapharma
    Sangamo Biosciences
    Spark Therapeutics
    Swedish Orphan Biovitrum

    Buy now